Our Abpromise guarantee covers the use of ab58367 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesWB: Use at a concentration of 1-5 µg/ml.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionAssociates with IL12RB1 to form the interleukin-23 receptor. Binds IL23 and mediates T-cells, NK cells and possibly certain macrophage/myeloid cells stimulation probably through activation of the Jak-Stat signaling cascade. IL23 functions in innate and adaptive immunity and may participate in acute response to infection in peripheral tissues. IL23 may be responsible for autoimmune inflammatory diseases and be important for tumorigenesis.
    • Tissue specificityExpressed by monocytes, Th1, Th0, NK and dendritic cells. Isoform 1 is specifically expressed in NK cells.
    • Involvement in diseaseGenetic variations in IL23R are associated with inflammatory bowel disease type 17 (IBD17) [MIM:612261]. IBD17 is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.
      Genetic variations in IL23R are a cause of susceptibility to psoriasis type 7 (PSORS7) [MIM:605606]. Psoriasis is a common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.
    • Sequence similaritiesBelongs to the type I cytokine receptor family. Type 2 subfamily.
      Contains 2 fibronectin type-III domains.
    • Post-translational
      Phosphorylated in response to IL23.
    • Cellular localizationCell membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • IL 23R antibody
      • IL-23 receptor antibody
      • IL-23R antibody
      • Il23r antibody
      • IL23R_HUMAN antibody
      • Interleukin 23 receptor antibody
      • Interleukin-23 receptor antibody
      see all

    Anti-IL23 Receptor antibody images

    • Predicted band size : 72 kDa
      IL23 Receptor antibody (ab58367) at 1ug/lane + A-431 cell lysate at 25ug/lane.

    References for Anti-IL23 Receptor antibody (ab58367)

    This product has been referenced in:
    • Quiniou C  et al. Specific targeting of the IL-23 receptor, using a novel small peptide noncompetitive antagonist, decreases the inflammatory response. Am J Physiol Regul Integr Comp Physiol 307:R1216-30 (2014). Read more (PubMed: 25354400) »

    See 1 Publication for this product

    Product Wall

    There are currently no Abreviews or Questions for ab58367.
    Please use the links above to contact us or submit feedback about this product.